TY - JOUR AU - Santonato, Daniela AU - Malvicini, María A. AU - Novau, Andrea AU - Torres, Silvio F. AU - Siaba Serrate, Alejandro AU - Romano, María V. AU - Brenzoni, Pablo G. AU - Fabbro, Leonardo AU - Paulosky, Laura AU - Cornistein, Wanda PY - 2022/05/27 Y2 - 2024/03/28 TI - Seroprevalence in Argentinian healthcare workers after vaccination with Sputnik V JF - International Journal of Infection Control JA - Int. j. infect. control VL - 18 IS - 0 SE - Original Articles DO - 10.3396/ijic.v18.21791 UR - https://ijic.info/article/view/21791 SP - AB - <p><strong>Background</strong>: Healthcare workers (HCW) were deeply affected by coronavirus disease 2019 (COVID-19). Therefore, vaccination of this population is crucial. However, data on Sputnik V vaccine are sparse.</p><p><strong>Objective:</strong>&nbsp;The aim of this study was to evaluate serological responses in HCWs following two doses of Sputnik V vaccine.</p><p><strong>Methods:</strong>&nbsp;A cross-sectional study was conducted at a tertiary-care private teaching hospital between April and May 2021. HCWs without a history of COVID-19 3 or more weeks after the second dose of Sputnik V had a fresh serum sample extracted and processed using Abbott® SARS-CoV-2 IgG II Quant. Values equal to or over 50 arbitrary units (AU)/mL were considered positive. Primary outcome was the proportion of participants who developed antibodies 21 or more days after the second dose of Sputnik V. Secondary outcomes were concentration of anti-spike IgG antibodies and comparison of such concentrations between samples taken 3–5 weeks and more than 5 weeks after the second dose.</p><p><strong>Results:</strong>&nbsp;The entire population developed anti-spike IgG antibodies. The median antibody concentration was 1234.8 AU/mL. When analysing days to extraction from second vaccine dose, there was no statistical difference between 21 and 35 days versus more than 35 days.</p><p><strong>Conclusion:</strong>&nbsp;Vaccination with Sputnik V in HCW at our institution demonstrated an efficacy of 100% in achieving quantifiable anti-spike IgG antibodies 21 or more days after the second dose.</p> ER -